National Bank of Canada’s Lineage Cell Therapeutics LCTX Stock Holding History

National Bank of Canada’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,250	Closed	-$570	–	3129
2025 Q1	$570	Hold	1,250	–	–	﹤0.01%	2634
2024 Q4	$629	Buy	1,250 +1,236	+8,829%	+$907	﹤0.01%	2701
2024 Q3	$13	Hold	14	–	–	﹤0.01%	2677
2024 Q2	$13	Hold	14	–	–	﹤0.01%	2672
2024 Q1	$16	Hold	14	–	–	﹤0.01%	2698
2023 Q4	$15	Hold	14	–	–	﹤0.01%	2689
2023 Q3	$16	Hold	14	–	–	﹤0.01%	2750
2023 Q2	$20	Hold	14	–	–	﹤0.01%	2700
2023 Q1	$21	Hold	14	–	–	﹤0.01%	2673
2022 Q4	$16	Hold	14	–	–	﹤0.01%	2741
2022 Q3	$0	Hold	14	–	–	﹤0.01%	2803
2022 Q2	$0	Hold	14	–	–	﹤0.01%	2901
2022 Q1	$0	Hold	14	–	–	﹤0.01%	2951
2021 Q4	$0	Buy	+14	New	+$33	﹤0.01%	2829

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

National Bank of Canada's LCTX Position: Q2 2025 in Review

National Bank of Canada sold out of Lineage Cell Therapeutics (LCTX) in Q2 2025, closing a stake of 1,250 shares — an estimated $570 sold.

National Bank of Canada first reported a position in LCTX in Q4 2021 and held it in 14 quarters. The position peaked at $629 in Q4 2024. 129 funds tracked by Wall St. Rank hold LCTX as of Q2 2025.

National Bank of Canada reported no remaining Lineage Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
National Bank of Canada sold 1,250 Lineage Cell Therapeutics shares in Q2 2025, an estimated $570.
National Bank of Canada first reported a position in Lineage Cell Therapeutics in Q4 2021 and held it in 14 quarters.
National Bank of Canada's Lineage Cell Therapeutics position peaked at $629 in Q4 2024.
129 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2025.

Based on National Bank of Canada's 13F filing for Q2 2025, filed 13 Aug 2025.